Technology
Health
Biotechnology

Motif Bio

$1.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.63%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Motif Bio and other stocks, options, ETFs, and crypto commission-free!

About

Motif Bio plc ADRs, also called Motif Bio, is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi). Read More The company was founded on November 20, 2014 and is headquartered in New York, NY.

Employees
8
Headquarters
New York, New York
Founded
2014
Market Cap
23.58M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
42.09K
High Today
$1.72
Low Today
$1.54
Open Price
$1.56
Volume
69.68K
52 Week High
$11.50
52 Week Low
$1.54

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO
US

News

Associated Press20h

Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments.

32
MarketBeatMar 8

Stock Price, News, & Analysis for MOTIF BIO PLC/S

Headlines about MTFB stock have been trending positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MOTIF BIO PLC/S earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out...

22
Associated PressFeb 18

Motif BioSciences Enters into Amendment Agreement with Hercules Capital

NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif BioSciences Inc. (a wholly owned subsidiary) has entered into an amendment agreement with its lender Hercules Capital, Inc (NYSE:HTGC) (“Hercules”) in relation to the loan agreement as notified on 15 November 2017. Pursuant to the amendment, Motif BioSciences Inc. will make an immediate early repayment of $7 million...

924
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.